Literature DB >> 32243795

The Emerging Landscape of Immune Cell Therapies.

Evan W Weber1, Marcela V Maus2, Crystal L Mackall3.   

Abstract

Cell therapies present an entirely new paradigm in drug development. Within this class, immune cell therapies are among the most advanced, having already demonstrated definitive evidence of clinical benefits in cancer and infectious disease. Numerous features distinguish these "living therapies" from traditional medicines, including their ability to expand and contract in proportion to need and to mediate therapeutic benefits for months or years following a single application. Continued advances in fundamental immunology, genetic engineering, gene editing, and synthetic biology exponentially expand opportunities to enhance the sophistication of immune cell therapies, increasing potency and safety and broadening their potential for treatment of disease. This perspective will summarize the current status of immune cell therapies for cancer, infectious disease, and autoimmunity, and discuss advances in cellular engineering to overcome barriers to progress.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32243795      PMCID: PMC8900215          DOI: 10.1016/j.cell.2020.03.001

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  222 in total

1.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

Review 2.  Interleukin-7: master regulator of peripheral T-cell homeostasis?

Authors:  T J Fry; C L Mackall
Journal:  Trends Immunol       Date:  2001-10       Impact factor: 16.687

3.  Redirecting gene-modified T cells toward various cancer types using tagged antibodies.

Authors:  Koji Tamada; Degui Geng; Yukimi Sakoda; Navneeta Bansal; Ratika Srivastava; Zhaoyang Li; Eduardo Davila
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

4.  Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells.

Authors:  Bertram Bengsch; Takuya Ohtani; Omar Khan; Manu Setty; Sasikanth Manne; Shaun O'Brien; Pier Federico Gherardini; Ramin Sedaghat Herati; Alexander C Huang; Kyong-Mi Chang; Evan W Newell; Niels Bovenschen; Dana Pe'er; Steven M Albelda; E John Wherry
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745

5.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

Review 6.  T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity.

Authors:  Jennifer D Stone; Adam S Chervin; David M Kranz
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

7.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

8.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

9.  CXCR5-Dependent Entry of CD8 T Cells into Rhesus Macaque B-Cell Follicles Achieved through T-Cell Engineering.

Authors:  Victor I Ayala; Claire Deleage; Matthew T Trivett; Sumiti Jain; Lori V Coren; Matthew W Breed; Joshua A Kramer; James A Thomas; Jacob D Estes; Jeffrey D Lifson; David E Ott
Journal:  J Virol       Date:  2017-05-12       Impact factor: 6.549

10.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

View more
  62 in total

1.  Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage.

Authors:  Alessio David Nahmad; Eli Reuveni; Ella Goldschmidt; Tamar Tenne; Meytal Liberman; Miriam Horovitz-Fried; Rami Khosravi; Hila Kobo; Eyal Reinstein; Asaf Madi; Uri Ben-David; Adi Barzel
Journal:  Nat Biotechnol       Date:  2022-06-30       Impact factor: 54.908

2.  The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets.

Authors:  Zhongyi Hu; Jiao Yuan; Meixiao Long; Junjie Jiang; Youyou Zhang; Tianli Zhang; Mu Xu; Yi Fan; Janos L Tanyi; Kathleen T Montone; Omid Tavana; Ho Man Chan; Xiaowen Hu; Robert H Vonderheide; Lin Zhang
Journal:  Nat Cancer       Date:  2021-12-13

Review 3.  Gene editing to enhance the efficacy of cancer cell therapies.

Authors:  Tara Murty; Crystal L Mackall
Journal:  Mol Ther       Date:  2021-10-18       Impact factor: 11.454

Review 4.  Charting roadmaps towards novel and safe synergistic immunotherapy combinations.

Authors:  Miguel F Sanmamed; Pedro Berraondo; Maria E Rodriguez-Ruiz; Ignacio Melero
Journal:  Nat Cancer       Date:  2022-06-28

5.  Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control.

Authors:  Ian C Miller; Ali Zamat; Lee-Kai Sun; Hathaichanok Phuengkham; Adrian M Harris; Lena Gamboa; Jason Yang; John P Murad; Saul J Priceman; Gabriel A Kwong
Journal:  Nat Biomed Eng       Date:  2021-08-12       Impact factor: 25.671

Review 6.  Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors:  Max Jan; Adam S Sperling; Benjamin L Ebert
Journal:  Nat Rev Clin Oncol       Date:  2021-03-02       Impact factor: 66.675

7.  Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.

Authors:  Max Jan; Irene Scarfò; Rebecca C Larson; Amanda Walker; Andrea Schmidts; Andrew A Guirguis; Jessica A Gasser; Mikołaj Słabicki; Amanda A Bouffard; Ana P Castano; Michael C Kann; Maria L Cabral; Alexander Tepper; Daniel E Grinshpun; Adam S Sperling; Taeyoon Kyung; Quinlan L Sievers; Michael E Birnbaum; Marcela V Maus; Benjamin L Ebert
Journal:  Sci Transl Med       Date:  2021-01-06       Impact factor: 17.956

Review 8.  Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.

Authors:  David A Braun; Ziad Bakouny; Laure Hirsch; Ronan Flippot; Eliezer M Van Allen; Catherine J Wu; Toni K Choueiri
Journal:  Nat Rev Clin Oncol       Date:  2021-01-12       Impact factor: 66.675

Review 9.  Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.

Authors:  Steven M Devine; Mary M Horowitz
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

10.  Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering.

Authors:  Jennifer R Hamilton; Connor A Tsuchida; David N Nguyen; Brian R Shy; E Riley McGarrigle; Cindy R Sandoval Espinoza; Daniel Carr; Franziska Blaeschke; Alexander Marson; Jennifer A Doudna
Journal:  Cell Rep       Date:  2021-06-01       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.